Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pteroate-rhodamine B conjugate is a fluorescently labeled small molecule bioconjugate designed for the targeted imaging of folate receptor (FR) positive tissues. It comprises a pteroate targeting ligand (a folate analog), a rhodamine B fluorescent reporter, and a chelating core capable of sequestering cytotoxic agents or radiotracers. Synthesized via solid-phase peptide synthesis, the conjugate selectively binds to folate receptors—which are overexpressed in various malignancies such as ovarian, lung, and endometrial cancers, as well as in certain inflammatory cells—and is internalized through receptor-mediated endocytosis. This makes it a versatile tool for fluorescence-guided intra-operative imaging and potential theranostic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pteroate-rhodamine B conjugate.